ArticleOncotarget2017

Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging.

Barbara Frigerio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.